473732-94-4

Usage

Uses

Used in Pharmaceutical and Medicinal Chemistry:
(R)-1-(5-Methylfuran-2-yl)propan-1-amine is used as an intermediate in the synthesis of pharmaceutical compounds due to its unique structural features and chiral nature. Its ability to participate in asymmetric synthesis and catalysis makes it a valuable component in the development of new drugs with improved efficacy and selectivity.
Used in Organic Synthesis:
In the field of organic synthesis, (R)-1-(5-Methylfuran-2-yl)propan-1-amine serves as a building block for the creation of more complex organic molecules. Its structural diversity and reactivity can be leveraged to synthesize a wide range of compounds with various applications.
Used in Drug Discovery and Development:
The potential biological activity of (R)-1-(5-Methylfuran-2-yl)propan-1-amine makes it a candidate for drug discovery and development. Its chiral properties and structural uniqueness could lead to the identification of novel therapeutic agents with specific targets and mechanisms of action.
Used in Asymmetric Synthesis and Catalysis:
(R)-1-(5-Methylfuran-2-yl)propan-1-amine is used as a chiral auxiliary or ligand in asymmetric synthesis and catalysis. Its presence can enhance the selectivity and yield of enantioselective reactions, which is crucial for the production of optically active compounds with desired biological properties.

Upstream product

• 620-02-0 5-Methylfurfural 

Downstream Products

• 473727-83-2 squaramide 
• 681510-52-1 C₁₉H₂₃N₅O₅S 
• 681513-53-1 C₂₀H₂₂F₃N₅O₄S 
• 1383453-71-1 C₂₀H₂₀N₂O₆ 
• 1383427-81-3 C₂₄H₂₇ClN₄O₇S 
• 1398584-34-3 C₂₇H₂₆N₂O₄ 
• 1398583-20-4 3-({[(1R)-1-(5-methyl-2-furyl)propyl](quinolin-3-ylcarbonyl)amino}methyl)benzoic acid 
• 1398583-84-0 methyl 3-({[(1R)-1-(5-methyl-2-furyl)propyl]amino}methyl)benzoate 

Relevant academic research and scientific papers

PROCESS FOR CONTROLLED CRYSTAL SIZE IN 1,2-SUBSTITUTED 3,4-DIOXO-1-CYCLOBUTENE COMPOUNDS

This application discloses a novel process for the preparation of 2-Hydroxy-N,N-dimethyl-3-[[2-[[1(R)-(5-methyl-2-furanyl)propyl]amino]-3,4-dioxo-1-cyclobuten-1-yl]amino]benzamide, which has utility, for example, in the treatment of CXC chemokine-mediated diseases.

PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 1,2-SUBSTITUTED 3,4-DIOXO-1-CYCLOBUTENE COMPOUNDS

This application discloses a novel process for the preparation of 1.2 - substituted 3, 4 - dioxo - 1 - cyclobutene compounds of formula (A), which have utility, for example, in the treatment of CXC chemokine -mediated diseases, and intermediates useful in the synthesis thereof.

Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5-methylfuran-2-yl) propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): A potent, orally bioavailable CXCR2/CXCR1 receptor antagonist

Structure-activity studies on lead cyclobutenedione 3 led to the discovery of 4 (SCH 527123), a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist with excellent cell-based activity. Compound 4 displayed good oral bioavailability in rat and may be a potential therapeutic agent for the treatment of various inflammatory diseases.

Synthesis of 2-hydroxy-N,N-dimethyl-3-[[2-[1(R)-(5-methyl-2-furanyl)propyl]amino]-3,4-dioxo-1-cyclobuten-1-l]aminobenzamide

Disclosed is a process for making the compound of formula I: using the compounds of formulas II, Q, and XI or XII: wherein A is selected from the group consisting of Br, Cl and I (with Br being preferred); and R represents (C1-C10)alkyl. Also disclosed are intermediate compounds that are made in the disclosed process.

THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of the formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula (IA).

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.